Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

• Main Authors: Zheng Tian, Ming Liu, Ya Zhang, Xin Wang
• Format: Article
• Language: English
• Published: BMC 2021-05-01
• Series: Journal of Hematology & Oncology
• Subjects: Bispecific T cell engager; Bispecific antibody; Cancer immunotherapy; Hematologic malignancy
• Online Access: https://doi.org/10.1186/s13045-021-01084-4

Abstract Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. The emerging bispecific antibodies (BsAbs), which recruit T cells to tumor cells, exemplified by bispecific T cell engagers (BiTEs), have facilitated the development of tumor immunotherapy. Here we discussed the advances and challenges in BiTE therapy developed for the treatment of hematologic malignancies. Blinatumomab, the first BiTE approved for the treatment of acute lymphocytic leukemia (ALL), is appreciated for its high efficacy and safety. Recent studies have focused on improving the efficacy of BiTEs by optimizing treatment regimens and refining the molecular structures of BiTEs. A considerable number of bispecific T cell-recruiting antibodies which are potentially effective in hematologic malignancies have been derived from BiTEs. The elucidation of mechanisms of BiTE action and neonatal techniques used for the construction of BsAbs can improve the treatment of hematological malignancies. This review summarized the features of bispecific T cell-recruiting antibodies for the treatment of hematologic malignancies with special focus on preclinical experiments and clinical studies.